Ropinirole is a non-ergot dopamine agonist selective for D2/D3 receptors, approved for Parkinson's disease and moderate-to-severe restless legs syndrome. Similar to pramipexole, it provides an alternative to levodopa in early PD and supplements levodopa therapy in advanced disease to smooth motor fluctuations.
Caution in patients with severe hepatic impairment
The bottom line
Evidence rating strong. Most-documented uses: effective monotherapy in early parkinson's disease, reduces levodopa dose requirements in advanced pd, fda-approved for restless legs syndrome. 10 sources indexed (2003–2024), with 1 interaction record on file.
The science
How it works, mechanistically.
Core mechanism
Acts as a full agonist at D2 and D3 dopamine receptors in the caudate-putamen of the striatum, mimicking the effects of endogenous dopamine. Provides continuous dopaminergic stimulation in contrast to the pulsatile stimulation of levodopa. Has negligible affinity for D1, 5-HT, or adrenergic receptors, contributing to its selectivity.
Class
Dopaminergic / Antiparkinson
Absorption
Water-soluble; take with food
Dosing
Dosing & protocol.
Common range
0.25 mg three times daily initially, titrated to 3-8 mg three times daily for PD; 0.25-4 mg once daily 1-3 hours before bedtime for RLS (as prescribed by your physician)
Recommended form
Immediate-release tablets; extended-release tablets (Requip XL) for once-daily dosing
Bioavailability ~50% due to first-pass metabolism; taking with food reduces nausea. Extensively metabolized by CYP1A2, smoking and ciprofloxacin significantly affect levels.
Safety
Full safety detail.
Side effects
Nausea and vomiting
Somnolence and sudden sleep attacks
Dizziness
Orthostatic hypotension
Impulse control disorders (gambling, hypersexuality, compulsive eating)
Ropinirole can cause somnolence and sudden sleep episodes, and melatonin can add sleep-promoting effects. This may be useful for nighttime sleep but can worsen next-day drowsiness, slowed reaction time, and falls. The risk is most important during ropinirole titration, in older adults, and when alcohol or other sedating medicines are also present.
Recommendation: Take melatonin only at bedtime and start with a low dose while using ropinirole. Avoid driving or hazardous work if you feel sleepy, and report sudden sleep episodes or new daytime sleepiness. Do not combine this pair with alcohol or extra sleep aids unless your prescriber is supervising it.
Soileau LG, Talbot NC, Storey NR et al.. Impulse control disorders in Parkinson's disease patients treated with pramipexole and ropinirole: a systematic review and meta-analysis. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2024
Kurin M, Bielefeldt K, Levinthal DJ. Prevalence of Nausea and Vomiting in Adults Using Ropinirole: A Systematic Review and Meta-Analysis. Digestive diseases and sciences. 2018
Quilici S, Abrams KR, Nicolas A et al.. Meta-analysis of the efficacy and tolerability of pramipexole versus ropinirole in the treatment of restless legs syndrome. Sleep medicine. 2008
Etminan M, Gill S, Samii A. Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson's disease: a meta-analysis. Drug safety. 2003
This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.
Use this with your stack
Ropinirole in NutriStack.
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.
NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.
NutriStack